Wiesław Świętnicki - Infectious Diseases

Author Information

Wiesław Świętnicki is a distinguished researcher affiliated with the Institute of Immunology and Experimental Therapy of the Polish Academy of Science, specifically within the Department of Immunology of Infectious Diseases in Wroclaw, Poland. His research primarily focuses on infectious diseases, with a significant interest in bacterial pathogens and their interactions with host organisms.

Research Contributions

Wiesław Świętnicki has made substantial contributions to the field of infectious diseases, particularly in understanding the mechanisms of bacterial pathogens and potential therapeutic targets. His work has explored various aspects of bacterial secretory systems, including the type II and type III secretion systems in Pseudomonas aeruginosa and Escherichia coli, which are crucial for bacterial virulence. He has also investigated the inhibitory potential of small molecule compounds against various bacteria such as Staphylococcus aureus and Proteus mirabilis. His research extends to exploring the biosynthetic pathways of lipopolysaccharide components and the interaction between Pseudomonas and Aspergillus. Świętnicki has also contributed to the development of potential prophylactic strategies against bacterial pathogens.

Aliases

Wiesław Świętnicki is also known by several aliases, including W Swietnicki, W. Swietnicki, and Wieslaw Swietnicki. These variations of his name are commonly used in his publications and professional references.

Publication and Citation Metrics

Metric	Value
Total Citation Count	2496
H-index	22
Total Paper Count	38

Publications:

Dihydrolipoamide Acetyltransferase AceF Influences the Type III Secretion System and Resistance to Oxidative Stresses through RsmY/Z in Pseudomonas aeruginosa

DOI: 10.3390/microorganisms10030666

Year: 2022

Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens

DOI: 10.3390/biom11060892

Year: 2021

Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica

DOI: 10.3390/ijms22136762

Year: 2021

Prediction of Selected Biosynthetic Pathways for the Lipopolysaccharide Components in Porphyromonas gingivalis

DOI: 10.3390/pathogens10030374

Year: 2021

Review of Potential Pseudomonas Weaponry, Relevant to the Pseudomonas–Aspergillus Interplay, for the Mycology Community

DOI: 10.3390/jof6020081

Year: 2020

Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa.

DOI: 10.1016/j.bbrc.2019.04.055

Year: 2019

In silico analysis of bacteriophage tail tubular proteins suggests a putative sugar binding site and a catalytic mechanism.

DOI: 10.1016/j.jmgm.2019.07.002

Year: 2019

Identification of small molecule compounds active against Staphylococcus aureus and Proteus mirabilis.

DOI: 10.1016/j.bbrc.2018.10.189

Year: 2018

Design of small molecule inhibitors of type III secretion system ATPase EscN from enteropathogenic Escherichia coli.

DOI: 10.18388/abp.2016_1265

Year: 2017

Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment

DOI: 10.3892/or.2014.3247

Year: 2014

Which Diseases Have Been Eradicated?

How Do Vaccines Help During Pandemics?

What Role Does WHO Play in Vaccination Programs?

How Can We Prevent Infections?

How Do Bacteria Cause Disease?

How to Interpret Chest CT Scan Results?

Which Infectious Diseases Commonly Cause Fatigue?

How Does the Inflammatory Response Work?

What are the Objectives of the RBM Partnership?

How Are Drug Targets Identified?

Partnered Content Networks

Relevant Topics